BACKGROUND: Methotrexate (MTX), a folic acid antagonist, is widely used as a cytotoxic chemotherapeutic agent for malignancies as well as in the treatment of various inflammatory diseases. The efficacy of this agent is often limited by severe side effects and toxic conditions. The present study was undertaken to determine whether N-acetylcysteine (NAC), as a potent antioxidant compound, could ameliorate MTX-induced oxidative liver damage. MATERIAL/ METHODS: A single dose of MTX (20 mg/kg, intraperitoneal) to rats was followed by intraperitoneal saline or NAC administration (150 mg/kg, MTX + NAC group) for the next 5 days. On the fifth day the rats were sacrificed and liver tissue samples were obtained and stored to measure reduced glutathione (GSH) and malondialdehyde (MDA) levels and myeloperoxidase (MPO), superoxide dismutase (SOD), and catalase (CAT) activity. RESULTS: MTX caused decreased GSH level and SOD and CAT activity and increased MDA level and MPO activity in the liver homogenates. These changes were significantly reversed by NAC treatment. CONCLUSIONS: These results confirm that administration of NAC decreases MTX-induced oxidative damage to the liver. These data indicate that NAC may be of therapeutic use in preventing hepatotoxicity in patients receiving MTX treatment.
BACKGROUND:Methotrexate (MTX), a folic acid antagonist, is widely used as a cytotoxic chemotherapeutic agent for malignancies as well as in the treatment of various inflammatory diseases. The efficacy of this agent is often limited by severe side effects and toxic conditions. The present study was undertaken to determine whether N-acetylcysteine (NAC), as a potent antioxidant compound, could ameliorate MTX-induced oxidative liver damage. MATERIAL/ METHODS: A single dose of MTX (20 mg/kg, intraperitoneal) to rats was followed by intraperitoneal saline or NAC administration (150 mg/kg, MTX + NAC group) for the next 5 days. On the fifth day the rats were sacrificed and liver tissue samples were obtained and stored to measure reduced glutathione (GSH) and malondialdehyde (MDA) levels and myeloperoxidase (MPO), superoxide dismutase (SOD), and catalase (CAT) activity. RESULTS:MTX caused decreased GSH level and SOD and CAT activity and increased MDA level and MPO activity in the liver homogenates. These changes were significantly reversed by NAC treatment. CONCLUSIONS: These results confirm that administration of NAC decreases MTX-induced oxidative damage to the liver. These data indicate that NAC may be of therapeutic use in preventing hepatotoxicity in patients receiving MTX treatment.
Authors: Gül Türkcü; Ulaş Alabalık; Ayşe Nur Keleş; Mehtap Bozkurt; İbrahim İbiloğlu; Uğur Fırat; Hüseyin Büyükbayram Journal: Int J Clin Exp Med Date: 2015-09-15
Authors: Marilyn J Hockenberry; Kevin R Krull; Kathleen C Insel; Lynnette L Harris; Patricia M Gundy; Kristin B Adkins; Alice E Pasvogel; Olga A Taylor; Kari M Koerner; David W Montgomery; Adam K Ross; Adam Hill; Ida M Moore Journal: Oncol Nurs Forum Date: 2015-09 Impact factor: 2.172
Authors: Hasan Kahraman; Ergül Kurutaş; Mahmut Tokur; Selim Bozkurt; Harun Cıralık; Betül Kabakcı; Nurhan Köksal; Vedat Balkan Journal: Balkan Med J Date: 2013-03-01 Impact factor: 2.021
Authors: Fahrettin Yildiz; Sacit Coban; Alpaslan Terzi; Mustafa Ates; Nurten Aksoy; Hale Cakir; Ali Riza Ocak; Muharrem Bitiren Journal: World J Gastroenterol Date: 2008-09-07 Impact factor: 5.742